Department of Surgery, St Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY 10025, USA.
Prog Cardiovasc Dis. 2012 May-Jun;54(6):529-34. doi: 10.1016/j.pcad.2012.03.005.
Unique genetic characteristics of hypertrophic cardiomyopathy (HCM), including heterogeneity and incomplete penetrance, have made making predictions about prognosis complex. We reviewed data from septal myectomy results as published from 1980 to 2011, most of which come from specialized tertiary care centers. We also performed a retrospective review of 132 consecutive patients who underwent HCM surgery at our institution. At a mean follow-up of 4.2 ± 3.2 years (range, 3 days to 14.2 years), there were no deaths within 30 days of surgery for our cohort. Over the course of 15 years, 2 deaths occurred in older patients, both of whom had surgery for HCM along with additional cardiac procedures. Age, the presence of comorbidities, and concomitant cardiac procedures were not statistically significant risk factors for mortality. Overall survival at 1, 5, and 10 years was excellent: 99%, 99%, and 92%, respectively. Surgical myectomy has been proven to be a safe and effective procedure for symptomatic obstructive HCM, and it confers excellent survival similar to that of the healthy population.
肥厚型心肌病(HCM)具有独特的遗传特征,包括异质性和不完全外显率,这使得预测预后变得复杂。我们回顾了 1980 年至 2011 年发表的关于间隔心肌切除术结果的数据,其中大部分来自专门的三级保健中心。我们还对在我们机构接受 HCM 手术的 132 例连续患者进行了回顾性分析。在平均 4.2±3.2 年(范围为 3 天至 14.2 年)的随访中,我们的队列中没有患者在手术后 30 天内死亡。在 15 年的时间里,有 2 名老年患者死亡,他们都因 HCM 以及其他心脏手术而接受了手术。年龄、合并症的存在和同时进行的心脏手术并不是死亡的统计学显著危险因素。总体生存率在 1、5 和 10 年时非常好:分别为 99%、99%和 92%。心肌切除术已被证明是一种安全有效的治疗梗阻性肥厚型心肌病的方法,它提供的生存率与健康人群相似。